[-] Show simple item record

dc.contributor.authorWinklerPrins, Vincent J.eng
dc.contributor.authorWeismantel, Arlene McFarlineng
dc.date.issued2004-10eng
dc.description.abstractColchicine (strength of recommendation [SOR]: B, based on 1 double-blind crossover study), allopurinol (SOR: B, based on 2 cohort studies), and weight loss (SOR: B, based on 1 small cohort study) have been shown to reduce symptomatic recurrences of gout, although the data to support their use is limited. Some evidence suggests that despite their serum uric acid-lowering effects, uricosurics (such as probenecid) fail to reduce gout attacks (SOR: B, based on 2 cohort studies). We were unable to find any double-blind, placebo-controlled long-term outcome studies addressing this problem.eng
dc.identifier.citationJournal of Family Practice, 53(10) 2004: 837-838.eng
dc.identifier.urihttp://hdl.handle.net/10355/3075eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2004 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.subjecturicosuricseng
dc.subjectinflammatory responseeng
dc.subject.lcshWeight losseng
dc.subject.lcshGouteng
dc.subject.lcshColchicineeng
dc.titleHow effective is prophylactic therapy for gout in people with prior attacks?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record